New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
16:02 EDTBSTC, AUXLBioSpecifics announces filing by Sobi for EU approval of XIAPEX
BioSpecifics Technologies (BSTC) announced today that Swedish Orphan Biovitrum AB, or Sobi, has filed for an extension of the label for XIAPEX with the European Medicines Agency to include the indication of Peyronie's disease. XIAPEX is currently approved for the treatment of Dupuytren's contracture in adult patients with a palpable cord. BioSpecifics' partner, Auxilium Pharmaceuticals (AUXL), is partnered with Sobi for the marketing of XIAPEX in 71 Eurasian and African countries for the treatment of Dupuytren's contracture, and Peyronie's disease pending applicable regulatory approvals.
News For BSTC;AUXL From The Last 14 Days
Check below for free stories on BSTC;AUXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
17:40 EDTBSTCBioSpecifics announces positive data from phase 2a study of CCH
Subscribe for More Information
09:07 EDTAUXLOn The Fly: Pre-market Movers
Subscribe for More Information
07:32 EDTAUXLAuxilium announces positive data from Phase 2a study of CCH with cellulite
Subscribe for More Information
August 18, 2014
11:41 EDTAUXLCubist rises after report sparks takeover interest speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use